Krystal Biotech, Inc. financial data

Symbol
KRYS on Nasdaq
Location
2100 Wharton Street, Suite 701, Pittsburgh, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 911 % -14.7%
Quick Ratio 34.8 % +72.6%
Debt-to-equity 9.71 % +19.3%
Return On Equity 19.4 % +205%
Return On Assets 17.7 % +201%
Operating Margin 42.4 % +272%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29M shares +0.82%
Common Stock, Shares, Outstanding 29M shares +0.79%
Entity Public Float 4.6B USD +64.3%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 29M shares +0.83%
Weighted Average Number of Shares Outstanding, Diluted 29.8M shares -0.23%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 373M USD +54.5%
Research and Development Expense 56.8M USD +10.4%
Operating Income (Loss) 158M USD +475%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 187M USD +61.1%
Income Tax Expense (Benefit) -12M USD -1313%
Net Income (Loss) Attributable to Parent 199M USD +280%
Earnings Per Share, Basic 6 USD/shares +237%
Earnings Per Share, Diluted 6 USD/shares +221%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 393M USD +4.98%
Cash, Cash Equivalents, and Short-term Investments 731M USD +24.3%
Accounts Receivable, after Allowance for Credit Loss, Current 130M USD +33.2%
Inventory, Net 37.6M USD +103%
Assets, Current 926M USD +29.8%
Deferred Income Tax Assets, Net 24.7M USD
Property, Plant and Equipment, Net 149M USD -4.93%
Operating Lease, Right-of-Use Asset 7.45M USD +15.1%
Other Assets, Noncurrent 333K USD +64%
Assets 1.24B USD +26.2%
Accounts Payable, Current 2.1M USD -62.4%
Liabilities, Current 91.3M USD +1.95%
Operating Lease, Liability, Noncurrent 7.81M USD +26.3%
Other Liabilities, Noncurrent 3.14M USD +312%
Liabilities 102M USD +5.96%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.1M USD -27.2%
Retained Earnings (Accumulated Deficit) -27.2M USD +88%
Stockholders' Equity Attributable to Parent 1.14B USD +28.5%
Liabilities and Equity 1.24B USD +26.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 31M USD +94.9%
Net Cash Provided by (Used in) Financing Activities -12.5M USD -218%
Net Cash Provided by (Used in) Investing Activities -54.8M USD -111%
Common Stock, Shares Authorized 80M shares 0%
Common Stock, Shares, Issued 29M shares +0.79%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -36.1M USD -5424%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 393M USD +4.98%
Deferred Tax Assets, Valuation Allowance 68.1M USD -11.6%
Deferred Tax Assets, Gross 83.1M USD -9.24%
Operating Lease, Liability 9.51M USD +27.2%
Depreciation 5.55M USD -8.13%
Payments to Acquire Property, Plant, and Equipment 6.2M USD +392%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 198M USD +266%
Lessee, Operating Lease, Liability, to be Paid 17.4M USD +16.1%
Property, Plant and Equipment, Gross 178M USD +0.94%
Operating Lease, Liability, Current 1.7M USD +31.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.92M USD +50.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.87M USD +46%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.91M USD +5.08%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.95M USD +50.3%
Deferred Tax Assets, Operating Loss Carryforwards 14.5M USD -63.6%
Unrecognized Tax Benefits 4.15M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.99M USD +50.2%
Additional Paid in Capital 1.16B USD +4.82%
Deferred Tax Assets, Net of Valuation Allowance 15M USD +3.03%